Solid Biosciences says FDA lifts halt on gene remedy trial, shares waft

Solid Biosciences says FDA lifts halt on gene remedy trial, shares waft

(Reuters) – Solid Biosciences Inc said on Thursday the U.S. Food and Drug Administration (FDA) has lifted the clinical halt placed on a trial of its experimental gene therapy for Duchenne muscular dystrophy (DMD), a muscle-wasting disorder.The news sent the company‚Äôs shares 75% higher in premarket trading, with Solid Biosciences saying it expects to restart…

View More Solid Biosciences says FDA lifts halt on gene remedy trial, shares waft